Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Department of Dermatology, Babol University of Medical Sciences, Babol, Iran.
Dermatol Ther. 2022 May;35(5):e15430. doi: 10.1111/dth.15430. Epub 2022 Mar 22.
SARS-CoV2 vaccines were approved without long-term monitoring due to emergent situations. This has raised some issues about timing and protocol of receiving vaccines in specific situations including patients with chronic inflammatory disorders such as psoriasis. Here, we present different aspects of SARS-CoV-2 infection and vaccination in psoriasis patients and aim to provide solutions to overcome the potential challenges. In brief, the benefits of vaccination outweigh the potential risk; vaccine-triggered de novo or flares of psoriasis is uncommon. As such, all psoriasis patients, especially those receiving systemic treatments including anti tumor necrosis factor agents, are strongly recommended to get SARS-CoV-2 vaccines. It is recommended that new immunosuppressive/immunomodulatory therapies be initiated at least 1 week after the second SARS-CoV-2 vaccine dose, if possible. In addition, in severe and active forms of psoriasis, it is better to delay vaccination until stabilization of the disease.
由于紧急情况，SARS-CoV-2 疫苗在没有长期监测的情况下获得批准。这就引发了一些关于在特定情况下（包括患有银屑病等慢性炎症性疾病的患者）接种疫苗的时间和方案的问题。在这里，我们介绍了 SARS-CoV-2 感染和接种疫苗在银屑病患者中的不同方面，并旨在提供解决方案以克服潜在的挑战。简而言之，接种疫苗的好处大于潜在风险；疫苗引发的银屑病新发病例或病情加重并不常见。因此，强烈建议所有银屑病患者，特别是那些正在接受包括抗肿瘤坏死因子制剂在内的全身治疗的患者，接种 SARS-CoV-2 疫苗。建议如果可能的话，在接种第二剂 SARS-CoV-2 疫苗至少 1 周后开始新的免疫抑制/免疫调节治疗。此外，对于严重和活跃的银屑病，最好等到疾病稳定后再接种疫苗。
